title: Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005.
abstract: BACKGROUND
  Influenza results in large numbers of secondary complications and hospitalizations.
  
  
  OBJECTIVE
  To assess the impact of oseltamivir on influenza-related complications and hospitalizations by analyzing health insurance claims data for 6 influenza seasons.
  
  
  METHODS
  A retrospective cohort study utilizing claims data from the 2000-2005 influenza seasons.
  
  
  METHODS
  Claims data were obtained from Thomson Healthcare MarketScan Research Databases.
  
  
  METHODS
  Patients prescribed oseltamivir within 1 day of influenza diagnosis were compared to those prescribed no antiviral therapy (controls).
  
  
  RESULTS
  Frequencies of pneumonia, other respiratory illnesses, and otitis media, and rates of hospitalization, were compared for the oseltamivir and no antiviral groups. Expenditure was also analyzed. Relative risk (RR) for each outcome was assessed using Cox proportional hazards regression.
  
  
  RESULTS
  Overall, 31,674 patients received oseltamivir and were propensity matched to patients with no antiviral prescription. Oseltamivir reduced the risk of diagnosis of pneumonia by 15% (RR 0.85, 95% confidence interval [CI] 0.73, 0.98), other respiratory illnesses by 20% (RR 0.80, 95% CI: 0.76, 0.83), and otitis media and its complications by 31% (RR 0.69, 95% CI: 0.61, 0.79). The greatest reductions in pneumonia risk, of 57% and 52%, were observed for children aged 6-12 years (RR 0.43, 95% CI: 0.26, 0.71) and 1-2 years (RR 0.48, 95% CI: 0.24, 0.99), respectively. Overall, hospitalization rates were reduced by 38% (RR 0.62, 95% CI: 0.52, 0.74) in the oseltamivir group compared with the no antiviral group. Total adjusted expenditures in the oseltamivir and no antiviral groups were not significantly different.
  
  
  CONCLUSIONS
  Oseltamivir reduced the relative risk of influenza-related complications and hospitalization when prescribed immediately upon presentation of influenza.
authors.affiliation: Texas Medical Research Associates L.L.C., San Antonio, Texas, USA. PPeters856@aol.com
authors.forename: Patrick H
authors.initials: PH
authors.lastname: Peters
authors.forename: Anne
authors.initials: A
authors.lastname: Moscona
authors.forename: Kathy L
authors.initials: KL
authors.lastname: Schulman
authors.forename: Charles E
authors.initials: CE
authors.lastname: Barr
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007223:Infant; D007251:Influenza, Human / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D053139:Oseltamivir / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D053139:Oseltamivir